Shoulder implant showdown: which material works best?

NCT ID NCT05339815

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 205 people who had reverse shoulder replacement surgery with one of two types of glenosphere implants (the ball part of the joint). The goal was to see which implant material—cobalt-chromium or a special plastic—was safer and worked better over two years. Researchers checked for implant problems, pain, and shoulder function using patient surveys and X-rays.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
shoulder implant (glenosphere)
What this could lead to
If successful, this could help surgeons choose the best implant material for reverse shoulder replacements, improving patient outcomes.
What could go wrong
This is a completed study comparing existing devices, so it won't lead to a new treatment. Results may not apply to all patients or other implant brands.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

205 people

The number who actually took part.

Started

Oct 2022

Finished

Jan 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The eligible study population is the entire population that underwent a reverse shoulder arthroplasty performed with 36-mm CoCrMo versus 40-mm cross-linked UHMWPE glenospheres between January 1, 2013 and January 1, 2020 at Wrightington Hospital (UK) in accordance with the indication for use of the product.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient was treated with the SMR Reverse Shoulder System device (either with 36-mm CoCrMo glenosphere or 40-mm cross-linked UHMWPE glenosphere) between January 1, 2013 and January 1, 2020 as per Instruction for Use 2. Patient was an adult male or female and was 18 years of age or older at the time of surgery 3. Patient received the SMR Reverse Shoulder System for primary, fracture, or revision total shoulder replacement in a grossly rotator cuff deficient joint with severe arthroplasty 4. The patient's joint was anatomically and structurally suited to receive the selected implants, with a functional deltoid muscle 5. Surgery date is at least 24 months from screening of data 6. Patient has baseline radiographs and Oxford Shoulder Score Exclusion Criteria: 1 Patient was treated with the SMR Reverse Shoulder System device (either with 36-mm CoCrMo glenosphere or 40-mm cross-linked UHMWPE glenosphere) between January 1, 2013 and January 1, 2020 out of the Indications for Use

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arthroplasty, replacement, shoulder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Wrightington, Wigan and Leigh NHS Foundation Trust

    Wigan, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.